



CHEMISTRY & BIOLOGY INTERFACE

An official Journal of ISCB, Journal homepage; www.cbijournal.com

***In vitro* anti-HIV activity of diverse substituted nitrosopyrimidine analogues**

Najim A. Al-Masoudi,^{a,b*} Yossra A. March,^a Jenan J. Al-Ameri,^a Dawood S. Ali,^a and Christophe Pannecouque^c

^aDepartment of Chemistry, College of Science, University of Basrah, Basrah, Iraq

^b(Present address: Am Tannenhof 8, 78464 Konstanz, Germany)

^cKU Leuven, Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, B-3000 Leuven, Belgium

*E-mail: najim.al-masoudi@gmx.de

Received 21 February 2016; Accepted 6 April 2016

Abstract: A series of substituted nitrosopyrimidine analogues were evaluated *in vitro* against the replication of HIV-1 and HIV-2 in MT-4 cells using MTT method. 4,6-Diamino-5-nitrosopyrimidine (**23**) showed an IC₅₀ values of > 0.44 μM with SI <1. This means that **23** was cytotoxic to MT-4 cells at a CC₅₀ value of > 0.44 μM. In addition, 6-amino-5-nitroso-2-phenylpyrimidine-4-one (**22**) and phenyl (2,6-diamino-5-nitrosopyrimidin-4-yl) benzoate (**36**) were cytotoxic to MT-4 cells at concentration of 6.92 and 6.85 μM, respectively.

Keywords: Anti-HIV activity / Cytotoxicity / Nitrosopyrimidines

1. Introduction


Nitrosopyrimidines constitute a class of biologically relevant molecules, since exhibited activity as inhibitors of cyclin-dependent kinases (CDKs) (*e.g.*: **1** and **2**) [1] and of the DNA-repair protein *O*(6)-alkylguanine-DNA-alkyltransferase (AGT) **3** [2] leading to a renewed interest in the synthesis of these pyrimidine derivatives. Recently, Melguizo *et al.* [3-5] have synthesized several alkoxy-5-nitrosopyrimidine analogues, aiming to evaluate their various biological activity, since they reported some nitrosopyrimidines as potential antifungal

[6] and antibacterial agents [7]. In addition, pyrimidine and its derivatives demonstrated a diverse array of biological and pharmacological activities including antitumor [8-10], antimicrobial [11-14], and antihypertensive [15] as well as their cardiovascular [16] and diuretic [17] properties. Some pyrimidine analogues exhibited potent antiviral activity against a wide spectrum of unrelated viruses, such as poliovirus [18], and herpes virus [19] in addition to their activity as anti-HIV agents [20-22]. Two recent diarylpyrimidines (DAPY), rilpivirine [23] and etravirine [24, 25] have been classified as non-nucleoside

reverse transcriptase inhibitors (NNRTI's). Further, several pyrimidine derivatives exhibited significant antitumor activity as well *e.g.* imatinibmesylate (Gleevec) [26], a novel interesting agent for treatment of chronic Leukemia via the tyrosine kinase inhibition, contains a 2-amino-4-pyridylsubstituted pyrimidine moiety. 2,4-Diamino-*N*¹-6-diarylpyrimidines were reported as active agents in the proliferation of tumor cell lines *in vivo*, especially duodenum cancer [27]. Chauhan and Kumar [28] have reviewed extensively the biological significance of pyrazolo[3,4-*d*]pyrimidines.

Considering the significance of pyrimidines and in continuation of our ongoing work [29-33] on the synthesis and anti-HIV of various pyrimidine derivatives, we report here the anti-HIV activity of some substituted nitrosopyrimidine derivatives.

Some of the substituted nitrosopyrimidine derivatives presented in this study have been previously prepared in our laboratories meanwhile the other analogues were prepared by different groups [3-7, 34-36].



CDKs Inhibitors

AGT Inhibitor

3. Results and discussion

2.1. Chemistry

In the present study, the selected substituted 5-nitrosopyrimidine analogues **4-38** have been synthesized by different laboratories by various methods including the nitrosation of carbon 5 of substituted pyrimidines, aminolysis of the

2- or 4-alkoxy group to the corresponding 2- or 4-alkylamino-5-nitrosopyrimidine derivatives, or alkylation of the free amino groups at carbons 2, 4 or 6 of 5-nitrosopyrimidine scaffold. Figures 1-5 represent different series of substituted 5-nitrosopyrimidine analogues, which have been evaluated for their activity against HIV. To the best of our knowledge, no study concerning the anti-HIV activity of nitrosopyrimidine analogues has been reported.




Fig. 1. 1,3-dialkylamino, or diamino-6-alkylamino-5-nitrosopyrimidine-2,4-dione derivatives (**4-13**)




Fig. 2. 2,2-(Dimethylamino) or 2-amino-6-(methylamino) or 6-amino-5-nitrosopyrimidine-4-one derivatives (**15-19**), *N*¹-Me-2-methoxy- (**21**) and 2-phenyl- (**22**) analogues.




Fig. 3. *N*⁶-Amino-*N*⁴-(substituted amino)-2-(H, NH₂, alkyl, SMe or Ph)-5-nitrosopyrimidine derivatives (23-30) and 2,4,6-triacetamido analogue (31)




Fig. 4. 4-Alkoxy-*N*⁴-methyl or *N*-alkyl, SMe or Ph)-5-nitrosopyrimidine derivatives(32-36).




Fig. 5. 5-Amino-(4-methylamino)-5-nitrosopyrimidine-2-one (37) and 4,6-diamino analogue (38)

3. *In vitro* Anti-HIV Assay

Compounds 4-38 were tested for their *in vitro* anti-HIV-1 (strain III_B) and HIV-2 (strain ROD) activity in human T-lymphocyte (MT-4) cells, using MTT method [37]. The results are

summarized in Table 1, in which the data for lamivudine (3TC) [38] and nevirapine [39] were included for comparison purposes. Compound 23 was found to be the only compound from the series inhibiting HIV-1 and HIV-2 replication (IC₅₀ = >0.44 μM), but no selectivity can be witnessed selectivity index (SI < 1). Compounds 22 and 36 showed moderate activity against HIV-1 and HIV-2 with IC₅₀ values of >6.92 and >6.85 μM, respectively, with selectivity index (SI < 1). Such data means these compounds might be toxic at the therapeutic level. However, the potency of the compounds was much lower than the corresponding lead compounds, lamivudine (3TC) and nevirapine.

Appropriate reference compounds are always included in the experiments assessing the anti-HIV activity of new compounds. Our choice for 3TC and nevirapine as reference compounds is based on the fact that both nucleoside and nonnucleosides reverse transcriptase inhibitors (NRTIs, NNRTIs, respectively) are equipotent against HIV-1 and HIV-2.

With respect to SAR studies, the unsubstituted 5-nitrosopyrimidine analogue at carbon 2 (C₂-H), with two free amino groups at carbons 4 and 6 (compound 23) showed generally triggers better activity, when compared to other analogues having substituents at C-2. Although compounds 22 and 36 having phenyl and amino groups at carbon 2 respectively, but revealed a moderate activity in comparison for those of the other analogues of the series. Such activity might be due to the tolerated of both compounds in the hydrophobic region of HIV RT. In conclusion, the unsubstituted carbon 2 of 5-nitrosopyrimidine analogue was found to be a potent agent against HIV and it might be considered a promising agent for further structural modifications and pharmacological evaluation.

Table 1. *In vitro* anti HIV-1 and HIV-2 activity and cytotoxicity of new nitrosopyrimidine

derivatives

Comp	HIV-1 (III _B) IC ₅₀ (μM)	HIV-2 (ROD) IC ₅₀ (μM)	CC ₅₀ (μM)	SI (III _B)	SI (ROD)
4	>58.13	>58.13	58.13	<1	<1
5	>86.63	>86.63	86.63	<1	<1
6	>98.25	>98.25	98.25	<1	<1
7	>106.50	>106.50	106.5	<1	<1
8	>92.50	>92.50	92.50	<1	<1
9	>06.90	>106.90	106.9	<1	<1
10	>125.00	>125.00	125.0	<1	<1
11	>59.50	>59.50	59.50	<1	<1
12	>104.20	>104.20	104.2	<1	<1
13	>108.50	>108.50	108.5	<1	<1
14	>111.00	>111.00	111.0	<1	<1
15	>97.70	>97.70	97.70	<1	<1
16	>91.50	>91.50	91.50	<1	<1
17	> 64.50	>64.50	64.50	<1	<1
18	>56.35	>56.35	56.35	<1	<1
19	>89.68	>89.68	89.68	<1	<1
20	>66.45	>66.45	66.45	<1	<1
21	>13.45	>13.45	13.45	<1	<1
22	>6.92	>6.92	6.92	<1	<1
23	>0.44	>0.44	0.44	<1	<1
24	>102.60	>102.60	102.6	<1	<1
25	>125.00	>125.00	125.0	<1	<1
26	> 57.45	> 57.45	57.45	<1	<1
27	> 69.03	>69.03	69.03	<1	<1
28	>11.43	>11.43	11.43	<1	<1
29	>65.45	>65.45	65.45	<1	<1
30	>67.18	>67.18	67.18	<1	<1
31	>12.98	>12.98	12.98	<1	<1
32	>25.03	>25.03	25.03	<1	<1
33	>44.68	>44.68	44.68	<1	<1
34	> 66.55	>66.55	66.55	<1	<1
35	>68.33	>66.33	66.33	<1	<1
36	>6.85	>6.85	6.85	<1	<1
37	> 96.63	> 96.63	96.63	<1	<1
38	>101.00	>101.00	101.0	<1	<1
3TC	>0.58	>2.27	>20	>34	> 9
Nevir- apine	0.075	>4.00	>4.00	>53	X1

Anti HIV-1 activity measured with strain III_B; anti HIV-2 activity measured with strain ROD; IC₅₀ (μM): compound concentration required to achieve 50% protection of MT-4 cells from the HIV-1 and HIV-2 induced cytopathogenic effect; Average CC₅₀ (μM) compound concentration that reduced the viability of mock-infected MT-4 cells by 50%; SI: selectivity index (CC₅₀/IC₅₀). Data represent mean values (± S.D.) for two independent determinations.

4. Conclusion

In summary, a series of substituted nitrosopyrimidine analogues (**4-38**) has been evaluated against HIV activity. Compound **23** having 2,4-diamino groups with unsubstituted carbon 2 (C₂-H) is the most active analogue of the series, meanwhile **23** and **36** exhibited moderate activity against HIV. Due to the cytotoxicity of these three analogues, they are in progress for antitumor evaluation.

Acknowledgement

We thank Professor W. Pfeleiderer of the Chemistry Department, University of Konstanz, Germany, for providing us some nitrosopyrimidine derivatives.

References

1. a) F. Marchetti, K. L. Sayle, J. Bentley, W. Clegg, N. J. Curtin, J. A. Endicott, B. T. Golding, R. J. Griffin, et al., *Org. Biomol. Chem.* **2007**, 10, 1577-1585; b) V. Mesguiche, R. J. Parsons, C. E. Arris, J. Bentley, F. T. Boyle, N. J. Curtin, T. G. Davies, et al., *Bioorg. Med. Chem. Lett.* **2003**, 13, 217-222; c) K. L. Sayle, J. Bentley, F. T. Boyle, A. H. Calvert, Y. Cheng, N. J. Curtin, J. A. Endicott, et al., *Bioorg. Med. Chem. Lett.* **2003**, 13, 3079-3082; d) C. E. Arris, F. T. Boyle, A. H. Calvert, N. J. Curtin, J. A. Endicott, E. F. Garman, A. E. Gibson, et al., *J. Med. Chem.* **2000**, 43, 2797-2804.
2. a) I. Terashima, K. Kohda, *J. Med. Chem.* **1998**, 41, 503-508; b) M.-Y. Chae, K. Swenn, S. Kanugula, M. Dolan, A. E. Pegg, R. C. Moschel, *J. Med. Chem.* **1995**, 38, 359-365; c) C. E. Arris, F. T. Boyle, A. H. Calvert, N. J. Curtin, J. A. Endicott, E. F. Garman, A. E. Gibson, et al., *J. Med. Chem.*

- 2000**, 43, 2797-2804.
3. A. Marchal, M. Nogueras, A. Sánchez, J. N. Low, L. Naesens, E. De Clercq, M. Melguizo, *Eur. J. Org. Chem.* **2010**, 3823-3830.
 4. A. Marchal, M. Melguizo, M. Nogueras, A. Sánchez, J. N. Low, *Synlett* **2002**, 255-258.
 5. M. Melguizo, A. Marchal, M. Nogueras, A. Sánchez, J. N. Low, *J. Heterocycl. Chem.* **2002**, 39, 97-103.
 6. M. Olivella, A. Marchal, M. Nogueras, A. Sánchez, M. Melguizo, M. Raimondi, S. Zaccchino, F. Giannini, J. Cobo, R. D. Enriz, *Bioorg. Med. Chem.* **2012**, 20, 6109-6122.
 7. M. Olivella, A. Marchal, M. Nogueras, M. Melguizo, B. Lima, A. Tapia, G. E. Feresin, et al., *Arch. Pharmazie* **2015**, 348, 68-80.
 8. M. T. Cocco, C. Congiu, V. Lilliu, *Bioorg. Med. Chem.* **2006**, 14, 366-372.
 9. J. F. Beattie, G. A. Breault, R. P. A. Ellston, S. Green, P. J. Jewsbury, C. J. Midgley, R. T. Naven, et al. *Bioorg. Med. Chem. Lett.* **2003**, 13, 2955-2960.
 10. H. Kimura, T. Katoh, T. Kajimoto, M. Node, M. Hisaki, Y. Sugimoto, T. Majima, Y. Uehara, T. Yamori, *Anticancer Res.* **2006**, 26, 91-97.
 11. D. H. Patel, B. D. Mistry, K. R. Desai, *Indian J. Hetero. Chem.* **2003**, 13, 179-180.
 12. S. H. Bantawal, M. Manjathuru, K. S. Mari, K. M. Padiyath, *Bioorg. Med. Chem.* **2006**, 14, 2040-2047.
 13. P. Sharma, N. Rane, V. K. Gurram, *Bioorg. Med. Chem. Lett.* **2004**, 14, 4185-4190.
 14. A. B. Adnan, T. Z. Hesham, A. F. Sherif, M. B. Azza, *Eur. J. Med. Chem.* **2003**, 38, 27-36.
 15. R. K. Russell, J. B. Press, R. A. Rampulla, J. J. McNally, R. Falotico, J. A. Keiser, *J. Med. Chem.* **1988**, 31, 1786-1793.
 16. V. Ralvic, G. Burnstock, *Drug News Perspect* **2003**, 16, 133-140.
 17. A. Monge, V. Martinez-Merino, C. Sanmartin, F. J. Fernandez, M. C. Ochoa, C. Bellver, P. Artigas, *Arznei-Forschung* **1990**, 40, 1230-1233.
 18. J. D. Gracil, D. A. Harki, V. S. Korneeval, J. P. Edathil, K. Too, D. Franco, et al., *J. Virol.* **2007**, 81, 11256-11266.
 19. M. N. Prichard, D. C. Quenelle, C. B. Hartline, E. A. Harden, G. Jefferson, S. L. Frederick, S. L. Daily, R. J. Whitley, K. N. Tiwari, J. A. Maddry, J. A. Secrist, E. R. Kern, *Antimicrob. Agents Chemother.* **2009**, 53, 5251-5285.
 20. T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R. T. Walker, J. Balzarini, E. De Clercq, *J. Med. Chem.* **1989**, 32, 2507-2509.
 21. H. Tanaka, H. Takashima, M. Ubasawa, K. Sekiya, I. Nitta, M. Baba, S. Shigeta, R. T. Walker, E. De Clercq, T. Miyasaka, *J. Med. Chem.* **1992**, 35, 337-345.
 22. J. Balzarini, M. Baba, E. De Clercq, *Antimicrob. Agents Chemother.* **1995**, 39, 998-1002.
 23. P. A. Janssen, P. J. Lewi, E. Arnold, F. Daeyaert, M. de Jonge, J. Heeres, L. Koymans, M. Vinkers, et al., *J. Med. Chem.* **2005**, 48, 1901-1909.
 24. D. W. Ludovici, B. L. de Corte, M. J. Kukla, H. Ye, C. Y. Ho, M. A. Lichtenstein, R. W. Kavash, K. Andries, et al., *Bioorg. Med. Chem.* **2001**, 11, 2235-2239.
 25. K. Das, A. D. Clark, P. J. Lewi, J. Heeres; M. R. de Jonge, L. M. H. Koymans; M. Vinkers, et al., *J. Med. Chem.* **2004**, 47, 2550-2560.
 26. V. K. Pindola, B. J. Zarowitz, *Pharmacother.* **2002**, 22, 1249-1265.
 27. B. Gong, F. Hong, K. Kohm, S. Jenkins, J. Tulinsky, R. Bhatt, P. de Vries, J. W. Singer, P. P. Klein, *Bioorg. Med. Chem. Lett.* **2004**, 14, 2303-2308.
 28. M. Chauhan, R. Kumar, *Bioorg. Med. Chem.* **2013**, 15, 5657-5668.
 29. N. A. Al-Masoudi, N. N. A. Jafar, S. J. Baqir, C. Pannecouque, P. Leyssen, J. Neyts, *J. Antivir. Chem. Chemother.* **2012**, 23, 103-112.
 30. N. A. Al-Masoudi, A. G. Kassim, N. A. Abdul-Reda, *Nucleos. Nucleot. Nucl.* **2014**, 33, 141-161.
 31. N. A. Al-Masoudi, Y. A. Marich, N. J. Al-Salihi, B. Saeed, *Z. Naturforsch.* **2014**, 69b, 913-923.
 32. Y. A. Marich, N. J. Al-Salihi, N. A. Al-Masoudi, *Eur. J. Chem.* **2014**, 4, 588-594.
 33. N. A. Al-Masoudi, B. A. Saeed, D. S. Ali, R. S. Alias, N. N. A. Jaffer, C. Pannecouque, *Chem. Biolo. Interface* **2016**, 6, 1-13.
 34. L. G. Frohlich, P. Kotsonis, H. Traub, S. Taghavi-Moghadam, N. Al-Masoudi, H. H. H. Strobel, H. Matter, W. Pfeleiderer, H. H. H. W. Schmidt, *J. Med. Chem.* **1999**, 42, 4108-4121.
 35. a) O. B. Riabova, V. A. Makarov, V. G. Granik, C. Párkányi, *J. Heterocycl. Chem.* **2008**, 45, 621-643; b) L. G. J. Hammarström, M. E. Meyer, D. B. Smith, F. X. Talamás, *Tetrahedron Lett.* **2003**, 44, 8361-8363; c) N. Baidur, N. Chadha, M. R. Player, *J. Comb. Chem.* **2003**, 5, 653-659; d) R. Di Lucrezia, I. H. Gilbert, D. D. Floyd, *J. Comb. Chem.* **2000**, 2, 249-253.
 36. J. H. Boyer, in: *The Chemistry of the Nitro and Nitroso Groups* (Ed.: H. Feuer), Wiley-Interscience, New York, **1970**, vol. 12, pp. 278-280.
 37. C. Pannecouque, D. Daelemans, E. De Clercq, *Nat. Protoc.* **2008**, 3, 427-434.
 38. J. A. Coates, N. Cammack, H. J. Jenkinson, A. J. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, J. M. Cameron, *Antimicrob. Agents Chemother.* **1992**, 36, 733-739.
 39. K. D. Hargrave, J. R. Proudfoot, K. G. Grozinger, E. Cullen, S. R. Kapadia, U. R. Patel, V. U. Fuchs, S. C. Mauldin, J. Vitous, M. L. Behnke, J. M. Klunder, K. Pal, J. W. Skiles, D. W. McNeil, J. M. Rose, G. C. Chow, M. T. Skoog, J. C. Wu, G. Schmidt, W. W. Engel, W. G. Eberlein, T. D., T. D. Saboe, S. J. Campbell, A. S. Rosenthal, *J. Med. Chem.* **1991**, 34, 2231-2241.